UPLC1/ASAP3 Antibody
Rabbit Polyclonal
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Background
This antibody is designed, produced, and validated as part of a collaboration between Rockland and the National Cancer Institute (NCI) and is suitable for Cancer, Immunology and Nuclear Signaling research. Anti-UPLC1 (up-regulated in liver cancer 1) / ASAP3 Antibody, also named DDEFL1 (development and differentiation-enhancing factor-like 1) or ASAP3, is a member of the AZAP family of proteins. These proteins catalyze the hydrolysis of GTP bound to ADP-ribosylation factor (Arf) proteins, thereby causing Arf inactivation. For this reason, the ASAPs are generally called ArfGAPs. The activity of ArfGAPs is dependent on the presence of phosphoinositides and is implicated in cellular processes such as membrane trafficking and remodeling of the actin cytoskeleton. ASAP3 has been found to be up-regulated in 80% of the hepatocellular carcinomas examined. Initial biochemical characterization reveals that ASAP3 shows class-specific GAP activity on Arf proteins, preferring Arf5 over Arf1 and Arf6. ASAP3 antibody has beed developed through the NCI antibody collaboration program and is ideal for Cancer and Signal Transduction research.
Product Details
Target Details
Application Details
Formulation
Shipping & Handling
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.